Publications by authors named "Angela Qu"

Claim this Profile
R
Regulatory, Translational, and Operational Considerations for the Incorporation of Biomarkers in Drug Development.
Heather Hatcher, Simona Stankeviciute, Chris Learn, Angela X Qu

Ther Innov Regul Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to Office Hysteroscopy in Fellowship Education and Practice.
Anna Zelivianskaia, Aparna R Ramanathan, Angela Qu, James K Robinson

J Minim Invasive Gynecol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting.
Jack Euesden, Sivakumar Gowrisankar, Angela Xiaoyan Qu, Pamela St Jean, Arlene R Hughes

Genes (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
Guru Sonpavde, Gregory R Pond, Stephanie Mullane, Angela Q Qu, Giuseppe Di Lorenzo, Joaquim Bellmunt

Clin Genitourin Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Guru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, Dean F Bajorin, Ashley M Regazzi, Angela Q Qu, Joaquim Bellmunt

Clin Genitourin Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
Guru Sonpavde, Joaquim Bellmunt, Jonathon E Rosenberg, Ashley M Regazzi, Dean F Bajorin, Angela Q Qu

Clin Genitourin Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Eliezer M Van Allen, Kent W Mouw, Philip Kim, Gopa Iyer, Nikhil Wagle, Angela Qu

Cancer Discov· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Toni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Leonard J Appleman

J Clin Oncol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
Gregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, Toni K Choueiri, Angela Qu

BJU Int· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Neeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, Kenneth M Boucher, Toni K Choueiri, Angela Q Qu

Clin Genitourin Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Gregory R Pond, Joaquim Bellmunt, Ronan Fougeray, Toni K Choueiri, Angela Q Qu

Clin Genitourin Cancer· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Toni K Choueiri, Suchun Cheng, Angela Q Qu, Jaromir Pastorek, Michael B Atkins

Urol Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
Guru Sonpavde, Gregory R Pond, Ronan Fougeray, Toni K Choueiri, Angela Q Qu, Joaquim Bellmunt

Eur Urol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression, fiber type, and strength are similar between left and right legs in older adults.
Mark Tarnopolsky, Stuart Phillips, Gianni Parise, Alex Varbanov, James Demuth, Angela Qu

J Gerontol A Biol Sci Med Sci· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: support for an endothelium-dependent mechanism.
Andrew N Carr, Brian W Howard, Hsiao T Yang, Elaine Eby-Wilkens, Paula Loos, Angela Qu

Cardiovasc Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis